GSK expands restructuring despite increase in sales and profits

Thursday 4 February 2010

GlaxoSmithKline is expanding its restructuring programme in order to generate an additional, annual pre-tax savings of £500 million by 2012. Half of the savings will come from R&D where it intends to stop discovery research in depression and pain.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

See map: Google Maps